title: [Clinical Research Progress on Transformed Lymphoma -Review].
abstract: Histologic transformation (HT) is a frequent event in the clinical course of patients with indolent lymphoma with dismal outcome. The diagnosis of HT is based on clinical manifestation, PET-CT and pathologic biopsy, and the latter is a golden standard for HT. There are contradictory data about the impact of initial management on the risk of transformation. Patients who present with HT did not receive R-CHOP or chemotherapy-naive, should receive this regimen. For the subset of patients received R-CHOP prior to HT, the second line chemotherapy for DLBCL should be adopted. Consolidation with HDT-ASCT should be considered for the suitable young patients. The radio-immunotherapy and novel drugs showed a bright perspective for the patients with HT.
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Bing-Jie
authors.initials: BJ
authors.lastname: Wang
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.E-mail：cenxn@aliyun.com.
authors.forename: Xi-Nan
authors.initials: XN
authors.lastname: Cen
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Han-Yun
authors.initials: HY
authors.lastname: Ren
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D006801:Humans; D008228:Lymphoma, Non-Hodgkin